怀孕期间肺癌的发病率增加是由于年轻女性吸烟、空气污染和高龄孕妇增加的缘故。这是第三例孕期接受阿雷替尼治疗的转移性阳性鲍曼氏肺腺癌女性病例报告。该患者在怀孕26周时确诊患有肺癌。她的情况迅速恶化并伴有弥漫性血管内凝血和低氧血症。经过5天的阿雷替尼600mg两次/天治疗和最佳支持性治疗后，患者的症状迅速缓解。她在怀孕39周时生下一个健康的男婴。出生时，母亲血浆中的阿雷替尼浓度比新生儿血浆中的浓度高4.3倍（299.0 vs 69.2ng/mL）。羊水和胎盘中的阿雷替尼浓度分别为27.3 ng/mL和1136.25 ng/g。母乳中的阿雷替尼浓度（152 ng/mL）表明该药物可以通过乳汁排泄。诊断后12个月，母亲康复良好，婴儿未观察到发育异常。版权所有©2023 Elsevier B.V.。

The incidence of lung cancer in pregnancy is increasing because of an increase in cigarette smoking among young women, air pollution, and advanced maternal age. This is the third case report of a woman with metastatic anaplastic lymphoma kinase (ALK)-positive lung adenocarcinoma treated with alectinib during pregnancy. The patient was diagnosed with lung cancer at 26 weeks' gestation. Her condition rapidly progressed to disseminated intravascular coagulation accompanied by hypoxemia. After 5 days of treatment with alectinib 600 mg twice daily and best supportive care, the patient's symptoms quickly resolved. She delivered a healthy male newborn at 39 weeks' gestation. At birth, the alectinib concentration was 4.3 times higher in maternal plasma than that in newborn plasma (299.0 vs 69.2 ng/mL). The concentrations of alectinib in the amniotic fluid and the placenta were 27.3 ng/mL and 1136.25 ng/g, respectively. The alectinib concentration in the maternal milk (152 ng/mL) indicated that this drug could be excreted through the breast milk. At 12 months after the diagnosis, the mother had recovered well, and no developmental anomalies were observed in the infant.Copyright © 2023 Elsevier B.V. All rights reserved.